OPKO HEALTH, INC.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

OPK$1.710.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets as of September 30, 2026

CONDENSED CONSO LIDATED BALANCE SHEET

(In thousands, except share and per share data)

	September 30, 2026	December 31, 2025
ASSETS
Current assets:
Cash, cash equivalents and current restricted cash	$390,220	$369,074
Accounts receivable, net	80,214	90,255
Inventory, net	50,601	52,733
Other current assets and prepaid expenses	37,183	56,729
Current assets held for sale	248,060	13,090
Total current assets	806,278	581,881
Property, plant and equipment, net	68,023	72,815
Intangible assets, net	396,168	446,428
In-process research and development	195,000	195,000
Goodwill	317,364	320,846
Investments	44,499	14,168
Operating lease right-of-use assets	33,883	37,153
Other assets	19,035	19,139
Noncurrent assets held for sale	—	244,513
Total assets	$1,880,250	$1,931,943
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$47,917	$41,103
Accrued expenses	84,081	84,406
Current maturities of operating leases	7,791	7,603
Current portion of lines of credit and notes payable	13,149	10,251
Current liabilities held for sale	9,418	3,314
Total current liabilities	162,356	146,677
Operating lease liabilities	26,840	30,083
Long term portion of convertible notes	92,458	85,020
Senior secured royalty financing	370,225	246,433
Deferred tax liabilities	96,674	126,241
Other long-term liabilities	15,523	22,798
Noncurrent liabilities held for sale	—	6,732
Total long-term liabilities	601,720	517,307
Total liabilities	764,076	663,984
Equity:
Common Stock - $0.01 par value, 1,250,000,000 shares authorized; 742,506,477 and 789,917,433 shares issued at September 30, 2026 and December 31, 2025, respectively	7,426	7,900
Treasury Stock - 30,849,907 shares at December 31, 2025	—	(3,176)
Additional paid-in capital	3,549,531	3,574,942
Accumulated other comprehensive loss	(33,295)	(21,017)
Accumulated deficit	(2,407,488)	(2,290,690)
Total shareholders’ equity	1,116,174	1,267,959
Total liabilities and equity	$1,880,250	$1,931,943

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

	For the three months endedSeptember 30,		For the nine months endedSeptember 30,
	2026	2025	2026	2025
Revenues:
Revenue from products	$41,811	$37,676	$122,795	$113,261
Licensing, collaboration and other revenue	23,603	18,749	83,661	45,978
Total revenues	65,414	56,425	206,456	159,239
Costs and expenses:
Cost of revenue	23,351	21,374	70,750	69,210
Selling, general and administrative	24,837	22,269	73,567	69,536
Research and development	32,177	29,797	94,254	90,345
Amortization of intangible assets	16,458	16,539	49,327	49,064
Total costs and expenses	96,823	89,979	287,898	278,155
Operating loss	(31,409)	(33,554)	(81,442)	(118,916)
Other income (expense), net:
Interest income	2,882	2,734	8,363	10,116
Interest expense	(13,451)	(11,326)	(35,735)	(97,034)
Fair value changes of derivative instruments, net	251	(38)	(112)	(295)
Other income (expense), net	3,861	1,216	4,065	(31,933)
Other expense, net	(6,457)	(7,414)	(23,419)	(119,146)
Loss before income taxes and investment losses	(37,866)	(40,968)	(104,861)	(238,062)
Income tax benefit	7,310	8,051	18,700	29,012
Net loss before investment losses	(30,556)	(32,917)	(86,161)	(209,050)
Loss from investments in investees	(5,000)	(3)	(5,002)	(12)
Net income (loss) from continuing operations	(35,556)	(32,920)	(91,163)	(209,062)
Income (loss) from discontinued operations, net of tax	(17,978)	54,551	(25,635)	14,639
Net income (loss)	$(53,534)	$21,631	$(116,798)	$(194,423)
Basic income (loss) per share:
Loss from continuing operations	$(0.05)	$(0.04)	$(0.12)	$(0.28)
Income (loss) from discontinued operations	$(0.02)	$0.07	$(0.03)	$0.02
Net income (loss) attributable to common shareholders	$(0.07)	$0.03	$(0.16)	$(0.26)
Diluted income (loss) per share:
Loss from continuing operations	$(0.05)	$(0.04)	$(0.12)	$(0.28)
Income (loss) from discontinued operations	$(0.02)	$0.07	$(0.03)	$0.02
Net income (loss) attributable to common shareholders	$(0.07)	$0.03	$(0.16)	$(0.26)
Weighted average common shares outstanding, basic	746,479,131	777,154,808	753,495,529	746,136,135
Weighted average common shares outstanding, diluted	746,479,131	777,154,808	753,495,529	746,136,135

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

	For the three months endedSeptember 30,		For the nine months endedSeptember 30,
	2026	2025	2026	2025
Net income (loss)	$(53,534)	$21,631	$(116,798)	$(194,423)
Other comprehensive income (loss), net of tax:
Change in foreign currency translation and other comprehensive income (loss)	(4,902)	(736)	(12,278)	30,664
Comprehensive income (loss)	$(58,436)	$20,895	$(129,076)	$(163,759)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.